NAUT

Nautilus Biotechnology, Inc. Health Care Laboratory Analytical Instruments Russell 3000

$2.73Close $345.3MMarket cap $0.89 – $3.2452-week range Jan 26, 2027Next report · estimated

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Dec 31, 2025 · filed Oct 27, 2026

Off 12-month high 16%

1wk 15.7% price change

1mo 92.3% price change

12-month return 194% total, dividends included

F-score — — Not assessed

Altman Z — Unknown

P/E — price / earnings

PEG — P/E / EPS growth

P/B 2.2× price / book

Earnings yield 17.7% EBIT / enterprise value

Cheaper than — of the market · not assessed

Revenue growth — year on year

EPS growth — latest quarter

Sales growth — latest quarter

ROE 32% return on equity

Free cash margin — -$52.0M FCF

D/E — long-term debt / equity

Net debt / EBITDA —

Interest cover —EBIT / interest

Trade setup

ATR% 15.6% $0.43 a day · 2×ATR $1.88

RS — vs the universe

Trend — trend template

Relative volume — vs 50-day average

Up/down volume — 50 sessions

Implied move — no scheduled report

Screen verdict

Did not qualify for any screen.

Warning signs

none flagged

No restatement or impairment
Equity positive
Interest covered
No material dilution
Profits tracking cash
Margins and revenue not shrinking

Last reported Oct 27, 2026

Last shock Oct 26, 2026-25% in one session2.3× volumeon results+12% since

Financials

6 fiscal years · from filings

Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology -$59.0M

Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology -$52.0M

Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology

Cash
Long-term debt

Shares outstanding Shares in issue at the year's end. A rising count means each share owns a smaller slice of the company (stock pay, share sales); a falling one, buybacks. The chart's scale is fitted to the count, so a small change looks large: read the percentage. Methodology 126.47m +282.4% since FY2020

	FY2020Dec 31, 2020	FY2021Dec 31, 2021	FY2022Dec 31, 2022	FY2023Dec 31, 2023	FY2024Dec 31, 2024	FY2025Dec 31, 2025
Net income	-$15.6M	-$50.3M	-$57.9M	-$63.7M	-$70.8M	-$59.0M
Earnings per share	-$0.54	-$0.60	-$0.46	-$0.51	-$0.56	-$0.47
Free cash flow	-$14.9M	-$41.5M	-$48.1M	-$54.2M	-$61.3M	-$52.0M
Cash	$36.6M	$185.6M	$114.5M	$19.4M	$27.6M	$12.4M
Shareholders' equity	-$29.7M	$363.6M	$314.9M	$265.4M	$208.7M	$157.0M
Shares outstanding	33.07m	124.30m	124.87m	125.07m	126.11m	126.47m

Filings

SEC EDGAR

Filed	Report	Period to	Lag
Oct 27, 2026	Quarterly ↗	Sep 30, 2026	27d
Jul 28, 2026	Quarterly ↗	Jun 30, 2026	28d
Apr 28, 2026	Quarterly ↗	Mar 31, 2026	28d
Feb 26, 2026	Annual ↗	Dec 31, 2025	57d
Oct 28, 2025	Quarterly ↗	Sep 30, 2025	28d
Jul 31, 2025	Quarterly ↗	Jun 30, 2025	31d
Apr 29, 2025	Quarterly ↗	Mar 31, 2025	29d
Feb 27, 2025	Annual ↗	Dec 31, 2024	58d
Oct 29, 2024	Quarterly ↗	Sep 30, 2024	29d
Jul 30, 2024	Quarterly ↗	Jun 30, 2024	30d
Apr 30, 2024	Quarterly ↗	Mar 31, 2024	30d
Feb 28, 2024	Annual ↗	Dec 31, 2023	59d

Current reports

Filed	Disclosed
Oct 27, 2026	Results ↗
Sep 11, 2026	Material agreement · Agreement ended ↗
Jul 28, 2026	Results ↗
Jun 18, 2026	Shareholder vote ↗
Apr 28, 2026	Results ↗
Feb 26, 2026	Results ↗
Nov 4, 2025	Other events ↗
Oct 28, 2025	Results ↗
Jul 31, 2025	Results ↗
Jun 23, 2025	Shareholder vote ↗
May 2, 2025	Listing notice ↗
Apr 29, 2025	Results ↗